Kringle PharmaKringle Pharma,Inc.4884東証グロース医薬品FY ending Sep 2025, non-consolidated, J-GAAP

What does Kringle Pharma do with its cash?

How cash from operations was spent on investment, dividends, buybacks and more.

Figures for this period are incomplete, so the chart cannot be drawn.

Cash flow ratios

Cash conversion, investment and shareholder payments calculated from disclosed figures.

Net income-¥916.3M

Operating cash flow-¥755.8M

Nonpositive profit and free cash flow are omitted as ratio denominators. Amounts use the period's reported currency.

Operating cash flow-¥755.8M

Net income-¥916.3M

Operating cash flow is the cash the core business actually brought in, including changes in receivables and inventory.
Free cash flow = operating cash flow − capital expenditure: a gauge of cash available for other uses.
Large "borrowing" or "cash drawdown" flows mean the company spent more than it generated that year.

Show source documents (6)

EDINET (FSA Japan)
有価証券報告書－第24期(2024/10/01－2025/09/30)
ID S100XBJD2025-12-19Open
EDINET (FSA Japan)
有価証券報告書－第23期(2023/10/01－2024/09/30)
ID S100UZTE2024-12-23Open
EDINET (FSA Japan)
有価証券報告書－第22期(2022/10/01－2023/09/30)
ID S100SJA82023-12-25Open
EDINET (FSA Japan)
有価証券報告書－第21期(令和3年10月1日－令和4年9月30日)
ID S100PVFJ2022-12-26Open
EDINET (FSA Japan)
有価証券報告書－第20期(令和2年10月1日－令和3年9月30日)
ID S100N50Z2021-12-27Open
EDINET (FSA Japan)
有価証券報告書－第19期(令和1年10月1日－令和2年9月30日)
ID S100KGH22020-12-28Open

Extracted from XBRL: 36 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.